The efficacy and safety of Fufangdanshen tablets (Radix Salviae miltiorrhizae formula tablets) for mild to moderate vascular dementia: a study protocol for a randomized controlled trial

Jinzhou Tian, Jing Shi, Mingqing Wei, Renan Qin, Jingnian Ni, Xuekai Zhang, Ting Li, Yongyan Wang, Jinzhou Tian, Jing Shi, Mingqing Wei, Renan Qin, Jingnian Ni, Xuekai Zhang, Ting Li, Yongyan Wang

Abstract

Background: Vascular dementia (VaD) is the second most common subtype of dementia after Alzheimer's disease (AD). Currently, there are no medications approved for treating patients with VaD. Fufangdanshen (FFDS) tablets (Radix Salviae miltiorrhizae formula tablets) are a traditional Chinese medicine that has been reported to improve memory. However, the existing evidence for FFDS tablets in clinical practice derives from methodologically flawed studies. To further investigate the safety, tolerability, and efficacy of FFDS tables in the treatment of mild to moderate VaD, we designed and reported the methodology for a 24-week randomized, double-blind, parallel, multicenter study.

Methods/design: This ongoing study is a double-blind, randomized, parallel placebo-controlled trial. A total of 240 patients with mild to moderate VaD will be enrolled. After a 2-week run-in period, the eligible patients will be randomized to receive either three FFDS or placebo tablets three times per day for 24 weeks, with a follow-up 12 weeks after the last treatment. The primary efficacy measurement will be the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and the Clinician Interview-Based Impression of Change (CIBIC-plus). The secondary efficacy measurements will include the Mini Mental State Examination (MMSE) and activities of daily living (ADL). Adverse events will also be reported.

Discussion: This randomized trial will be the first rigorous study on the efficacy and safety of FFDS tablets for treating cognitive symptoms in patients with VaD using a rational design.

Trial registration: ClinicalTrials.gov: NCT01761227 . Registered on 2 January 2013.

Keywords: Chinese medicine; Fufangdanshen tablets; Randomized controlled trial; Vascular dementia.

Figures

Fig. 1
Fig. 1
Schedule of enrollment. ITT intent to treat

References

    1. Dubois MF, Herbert R. The incidence of vascular dementia in Canada: a comparison with Europe and East Asia. Neuroepidemiology. 2001;20:179–87. doi: 10.1159/000054785.
    1. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurology. 2000;54(suppl 5):4–9.
    1. Dong MJ, Peng B, Lin XT, Zhao J, Zhou YR, Wang RH. The prevalence of dementia in the People’s Republic of China: a systematic analysis of 1980–2004 studies. Age Ageing. 2007;36:619–24. doi: 10.1093/ageing/afm128.
    1. Broich K. Outcome measures in clinical trials on medicinal products for the treatment of dementia: a European regulatory perspective. Internat Psychogeriatrics. 2007;19(3):509–24. doi: 10.1017/S1041610207005273.
    1. Li LX, Ru LQ. Influence of tanshinone on learning and memory impairment induced by amyloidβ-peptide1-40 in rats. Chin J Gerontology. 2003;23:294–7. Article in Chinese.
    1. Jiang P, Chen M, Lv J, Chen C, Jiao BH. Effect of tanshinoneIIA on MMP-2 and iNOS expression and free radical release in hippocampus of rat Alzheimer’s disease mode. Academic J Second Military Med Univ. 2010;31:380–4. Article in Chinese.
    1. Zhu YL, Yang WQ. Effects of Compound Tablet of Red Sage Root on the expression of VEGF in brain of rat during chronic cerebral ischemia. Chin J Practical Nervous Diseases. 2007;10:26–7. Article in Chinese.
    1. Wang NS, Liang MR, Liu QD, et al. An experimental study on the effects of borneol as adjuvant drug and messenger drug. J Traditional Chin Med. 1994;35:46–7. Article in Chinese.
    1. Zhao LG, Fang TH, Yuan DP. Effects of Fufang Danshen Tablets on the disturbance in learning and memorizing of vascular dementia mice. Lishizhen Medicine Materia Medical Res. 2006;17:959–60. Article in Chinese.
    1. Zhang Y, Lin Q, Tang MK, Xu QP, Sun JN. Effects of Fufangdanshen on cholineacetyl transferase and acetylcholinesterase activities of hippocampus and cerebral cortex in rats with senile dementia. J Beijing Univ Traditional Chin Med. 2008;31:192–5. Article in Chinese.
    1. Qin RA, Luo JB, Chen M, Huang ZY, Wang H, Yang DS, et al. Effect of Compound Danshen Tablets on amino acid neurotransmitters in brain of Alzheimer’s disease rats. Chin Traditional Herbal Drugs. 2004;35:905–7. Article in Chinese.
    1. Zhang XY, Qin X, Zhang YF, Lin J, Wang DQ, Qin RA. Protective effects of Compound Danshen Tablets on rat with vascular dementia caused by ischemia and reperfusion in middle cerebral artery. Pharmacol Clin Chin Materia Medica. 2015;01:177–80. Article in Chinese.
    1. Folstein M, Folstein S, McHugh P. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res. 1975;12:189–98. doi: 10.1016/0022-3956(75)90026-6.
    1. 14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revised. Washington, DC: American Psychiatric Association; 2000
    1. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurol. 1993;43:250–60. doi: 10.1212/WNL.43.2.250.
    1. Rosen W, Terry R. Pathological verification of ischemic score differentiation of dementias. Ann Neurol. 1980;7:486–8. doi: 10.1002/ana.410070516.
    1. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group Neurol. 1998;50:136–45.
    1. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62. doi: 10.1136/jnnp.23.1.56.
    1. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179–86. doi: 10.1093/geront/9.3_Part_1.179.
    1. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356–64. doi: 10.1176/ajp.141.11.1356.
    1. Reisberg B, Schneider L, Doody R, Anand R, Feldman H, Haraguchi H, et al. Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1997;11(suppl 3):8–18.
    1. Cai YQ, Yang X. The adverse events of the DiAoXinXueKang and FuFangDanShen tablets. Shan Dong J Traditional Chin Med. 2005;24:372–4.
    1. Wetterling T, Kanitz RD, Borgis KJ. Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN) Stroke. 1996;27:30–6. doi: 10.1161/01.STR.27.1.30.
    1. Gold G, Giannakopoulos P, Montes-Paixao Júnior C, Herrmann FR, Mulligan R, Michel JP, et al. Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia. Neurol. 1997;49:690–4. doi: 10.1212/WNL.49.3.690.
    1. Rockwood K, Davis H, MacKnight C, Vandorpe R, Gauthier S, Guzman A. The Consortium to Investigate Vascular Impairment of Cognition: methods and first findings. Can J Neurol Sci. 2003;30:237–43. doi: 10.1017/S0317167100002663.
    1. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on Medicinal Products for the Treatment of Alzheimer’s disease and Other Dementias. London: EMA; accessed in 2015. .
    1. Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G, European Task Force Group Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurol. 2008;7:436–50. doi: 10.1016/S1474-4422(08)70087-5.
    1. Leber P. Guidelines for the clinical evaluation of anti-dementia drugs. Washington, DC: Food & Drug Administration; 1990.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner